Enhanced cyclic guanosine monophosphate (cGMP) signaling may attenuate myocardial ischemia-reperfusion injury (I/R) and improve left ventricular (LV) functional recovery after myocardial infarction (MI). We investigated the cardioprotection afforded by inhaled NO (iNO), the phosphodiesterase 5 (PDE5)-specific inhibitor tadalafil (TAD), or their combination (iNO1TAD) in C57Bl6J mice subjected to 6-minute left anterior descending artery ligation followed by reperfusion. We measured plasma and cardiac concentrations of cGMP during early reperfusion, quantified myocardial necrosis and inflammation by serial troponin-I (TnI) and myeloperoxidase-positive cell infiltration at day 3, and evaluated LV function and remodeling after 4 weeks using echocardiography and pressure-conductance catheterization. Administration of iNO, TAD, or both during I/R was safe and hemodynamically well tolerated. Compared with untreated mice (CON), only iNO1TAD increased plasma and cardiac-cGMP levels during early reperfusion (80 6 12 versus 36 6 6 pmol/ml and 0.15 6 0.02 versus 0.05 6 0.01 pmol/mg protein, P , 0.05 for both). Moreover, iNO1TAD reduced TnI at 4 hours to a greater extent (P , 0.001 versus CON) than either alone (P , 0.05 versus CON) and was associated with significantly less myocardial inflammatory cell infiltration at day 3. After 4 weeks and compared with CON, iNO1TAD was associated with increased fractional shortening (43 6 1 versus 33 6 2%, P , 0.01), larger stroke volumes (14.9 6 1.2 versus 10.2 6 0.9 ml, P , 0.05), enhanced septal and posterior wall thickening (P , 0.05 and P , 0.001, respectively), and attenuated LV dilatation (P , 0.001), whereas iNO or TAD alone conferred less benefit. Thus, iNO1TAD has superior efficacy to limit early reperfusion injury and attenuate adverse LV remodeling. Combination of inhaled NO with a long-acting PDE5 inhibitor may represent a promising strategy to reduce ischemic damage following reperfusion and better preserve LV function.